Fuse Medical, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Fuse Medical, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $26.34M | Mar 21, 2019 |
| FY2018 | Dec 31, 2017 | $26.41M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $25.67M | Sep 21, 2018 |
| FY2015 | Dec 31, 2015 | $1.68M | Mar 25, 2016 |
| FY2015 | Dec 31, 2014 | $941.1K | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | $277.5K | Apr 15, 2015 |
| FY2014 | Aug 31, 2013 | $1.06M | Apr 15, 2015 |
| FY2014 | Dec 31, 2012 | $405.9K | Apr 15, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $18.64M | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | $20.41M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $21.40M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $22.90M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $26.34M | Mar 30, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $567.6K | Mar 20, 2017 |
| FY2016 | Dec 31, 2015 | $1.68M | Mar 20, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $11.54M | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | $11.94M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $12.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $11.14M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $12.99M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $11.82M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $14.41M | Sep 21, 2018 |
| FY2016 | Dec 31, 2015 | $1.01M | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | $455.7K | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | $194.4K | Apr 15, 2015 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $3.10M | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | ($1.59M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($1.43M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.32M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $3.96M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $699.7K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $3.02M | Sep 21, 2018 |
| FY2016 | Dec 31, 2015 | ($801.5K) | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | ($1.41M) | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | ($194.7K) | Apr 15, 2015 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($815.1K) | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | ($2.20M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($1.03M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.35M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.96M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $858.9K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $3.16M | Sep 21, 2018 |
| FY2016 | Dec 31, 2015 | ($794.4K) | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | ($1.33M) | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | ($194.4K) | Apr 15, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $6.54M | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | $7.01M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $6.54M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $8.47M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $8.47M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $5.32M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $4.17M | Sep 21, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $34.8K | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | ($1.78M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $236.7K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.7K) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.48M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $1.60M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $2.79M | Sep 21, 2018 |
| FY2015 | Dec 31, 2015 | ($375.1K) | Mar 25, 2016 |
| FY2015 | Dec 31, 2014 | ($1.17M) | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | ($84.5K) | Apr 15, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $20.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $15.3K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $41.8K | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $20.3K | Mar 21, 2019 |
| FY2016 | Dec 31, 2015 | $8.3K | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | $61.0K | Mar 25, 2016 |
| FY2014 | Aug 31, 2013 | $1.8K | Apr 15, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $19.76M | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | $18.30M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $17.42M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $18.38M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $22.17M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $19.25M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $19.58M | Sep 21, 2018 |
| FY2016 | Dec 31, 2015 | $435.0K | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | $545.9K | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | $535.0K | Apr 15, 2015 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $20.07M | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | $21.74M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $19.53M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $19.60M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $20.71M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $27.23M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $8.98M | Sep 21, 2018 |
| FY2016 | Dec 31, 2015 | $430.0K | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | $347.4K | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | $432.9K | Apr 15, 2015 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($310.9K) | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | ($3.43M) | Apr 14, 2023 |
| FY2022 | Dec 31, 2020 | ($2.11M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2019 | ($1.22M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $1.47M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | ($7.98M) | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $10.60M | Mar 21, 2019 |
| FY2017 | Dec 31, 2015 | $8.00M | Sep 21, 2018 |
| FY2016 | Dec 31, 2014 | $198.5K | Mar 20, 2017 |
| FY2015 | Dec 31, 2013 | $102.1K | Mar 25, 2016 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $1.97M | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | $1.97M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.97M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.97M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.91M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | $820.7K | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | $820.7K | Sep 21, 2018 |
| FY2017 | Dec 19, 2016 | $820.0K | Sep 21, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | ($2.52M) | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | ($5.62M) | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | ($4.03M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.60M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $720.7K | Mar 30, 2020 |
| FY2016 | Dec 31, 2016 | ($2.90M) | Mar 20, 2017 |
| FY2016 | Dec 31, 2015 | ($2.32M) | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | ($1.51M) | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | ($13.0K) | Apr 15, 2015 |
| FY2013 | Aug 31, 2013 | ($3.37M) | Nov 15, 2013 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $147.9K | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | $553.2K | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | $1.19M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.10M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $844.3K | Mar 30, 2020 |
| FY2019 | Dec 31, 2017 | $804.7K | Mar 30, 2020 |
| FY2018 | Dec 31, 2016 | $778.4K | Mar 21, 2019 |
| FY2017 | Dec 31, 2015 | $263.6K | Sep 21, 2018 |
| FY2016 | Dec 31, 2014 | $67.6K | Mar 20, 2017 |
| FY2015 | Dec 31, 2013 | $12.3K | Mar 25, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Sep 21, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 0 | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | 0 | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 0 | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Sep 21, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 73.90M | Apr 14, 2023 |
| FY2022 | Dec 31, 2021 | 72.90M | Apr 14, 2023 |
| FY2021 | Dec 31, 2020 | 73.12M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 73.12M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 74.60M | Mar 30, 2020 |
| FY2018 | Dec 31, 2017 | 65.89M | Mar 21, 2019 |
| FY2017 | Dec 31, 2016 | 15.89M | Sep 21, 2018 |
| FY2016 | Dec 31, 2015 | 6.89M | Mar 20, 2017 |
| FY2015 | Dec 31, 2014 | 5.51M | Mar 25, 2016 |
| FY2014 | Dec 31, 2013 | 3.60M | Apr 15, 2015 |